Page 85 - Oncology Coder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology coder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Coder Today - Breaking & Trending Today

Community Voices: Light the way to prostate cancer awareness

Another September, another Prostate Cancer Awareness Month. Where are the morning news segments throughout the month promoting men’s health and early detection. Where are the buildings around the city all ....

United States , Men Health , Prostate Cancer Awareness , African American , Specific Antigen , September Blue , Chool Systems ,

2 Minute Medicine Rewind September 18, 2023 | 2 Minute Medicine

Non-erosive gastro-oesophageal reflux disease and incidence of oesophageal adenocarcinoma in three Nordic countries: population based cohort study 1. Patients with non-erosive gastro-esophageal reflux disease (GERD) do not have an increased incidence of developing esophageal adenocarcinoma compared to the general population. Evidence Rating Level: 2 (Good) For patients with gastro-esophageal reflux disease (GERD), endoscopic findings of ....

South Korea , Rating Level , Numeric Pain Rating Scale , Pain Disability Index , Decision Regret Scale , Breast Cancer Treatment Outcomes Scale , Functional Assessment , Cancer Therapy , Charlson Comorbidity Index , Weekly Rewinds ,

State & Union: Prostate Cancer Awareness Month

The New York State Department of Health recognizes Prostate Cancer Awareness Month by encouraging men to get informed and take action to prevent and detect prostate cancer as early as ....

New York , United States , James Mcdonald , Us Preventive Services Task , York State Department Of Health , Centers For Disease , New York State Department , Prostate Cancer Awareness Month , Health Commissioner , Hispanic Black , Disease Control , Services Task , Task Force ,

Atezolizumab is a potentially effective treatment option for patients with alveolar soft part sarcoma

1. 37% of study patients had an objective response to treatment with atezolizumab. 2. Median progression-free survival was 20.8 months. Evidence Rating Level: 2 (Good) Study Rundown: Alveolar soft part sarcoma (ASPS) has no standardized therapy and is one of the rarest sarcomas with a low 5-year overall survival. Traditional chemotherapies are generally ineffective; however, ....

Minute Medicine Inc , Rating Level , Alveolar Soft Part Sarcoma , Chronic Disease ,

Patritumab Deruxtecan in EGFR-mutated NSCLC post EGFR TKI and Chemotherapy

1. The objective response rate was 29.8% (1% complete response, 66% partial response) with a PFS of 5.5 months and a median OS of 11.9 months. 2. 64.9% of treatment-emergent adverse events (TEAEs) of grade ≥3, in which thrombocytopenia and neutropenia were the most common. Evidence Rating Level: 2 (Good) Study Rundown: Salvage therapy is ....

Rating Level , Patritumab Deruxtecan , Mutated Non , Small Cell Lung , Egfr Nsclc , Chronic Disease ,